摘要
目的观察雷帕霉素联合环孢霉素A防治肾移植急性排斥反应的效果,探索新的免疫抑制方案。方法将该院2004年1月～2004年8月施行的尸体肾移植的受者共89例,分成两组,分别给予“CsA+MMF+Pred”方案(43例)和“CsA+RAPA+Pred”方案(46例),观察两组受者移植后3个月急性排斥反应发生率、肾功能、感染率及恶性肿瘤发生率、受者和移植肾存活情况。结果RAPA组受者急性排斥反应发生率明显降低(7.0%/20.9%),发生时间推迟(44.3±6.24/35.0±5.48)d,肾功能恢复提前(4.8±2.04/5.9±2.1)d。结论“CsA+RAPA+Pred”方案可以有效降低排斥反应发生率,促进肾功能恢复。
[Objective] To observe the effect of the combined ,egimen of Rapamycin and Cyclosporine on renal transplant recipients. [Methods] The recipients from 2004-01-01 to 2004-08-01 were divided into two groups, group A was given ＂CsA＋MMF＋Pred＂ regimen, group B was given the ＂CsA＋RAPA＋Pred＂ regimen. The rate of acute rejection, infection, malignancy and the time of the rejeeton onset and renal function were recorded. [Results] Group B had a lower acute rejection rate （7.0% VS 20.9%）, delayed onset of the rejection （44.3±6.24 VS 35.0±5.48） d and earlier renal function （4.8±2.04 VS 5.9±2.1） d. [Conclusion] ＂CsA＋RAPA＋Pred＂ regimen could be a good protocol for better results for renal transplants.
出处
《中国医学工程》
2006年第1期63-65,共3页
China Medical Engineering
